Adriamycin-CMF Regimen for High Risk Breast Cancer
Author Information
Author(s): Cameron D A, Anderson A, Toy E, Evans T R J, Le Vay J H, Kennedy I C S, Grieve R J, Perren T J, Jones A, Mansi J, Crown J, Leonard R C F
Primary Institution: Western General Hospital, Edinburgh, UK
Hypothesis
Is the block sequential adriamycin CMF regimen the optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
Conclusion
The adriamycin-CMF regimen is effective for high risk breast cancer patients, showing a 5-year disease-free survival of 61% and overall survival of 70%.
Supporting Evidence
- The overall 5-year disease-free survival is 61%.
- The overall survival is 70%.
- Patients treated with this regimen showed outcomes comparable to those in clinical trials.
- Tamoxifen was administered to over 90% of patients with ER positive tumours.
- Radiotherapy was given to 88% of patients.
Takeaway
This study looked at a treatment for women with serious breast cancer and found that it works well, helping many women live longer without cancer.
Methodology
Patients were treated with a regimen of four cycles of adriamycin followed by eight cycles of CMF, and outcomes were audited from ten centers.
Potential Biases
Data were collected from various centers without external validation, which could introduce bias.
Limitations
The study was retrospective and lacked external data audit, which may affect the reliability of the findings.
Participant Demographics
Median age of participants was 49 years, with a range from 26 to 73 years; most had at least four involved axillary nodes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website